Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 24, 2018

Primary Completion Date

June 24, 2027

Study Completion Date

June 24, 2027

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

Venetoclax

PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.

DRUG

Lenalidomide

10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.

DRUG

Rituximab

375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12

Trial Locations (3)

43210

NOT_YET_RECRUITING

The Ohio State University Comprehensive Cancer Center, Columbus

48109

NOT_YET_RECRUITING

University of Michigan, Ann Arbor

91010

RECRUITING

City of Hope Medical center, Duarte

All Listed Sponsors
lead

City of Hope Medical Center

OTHER